Tradestie Institutional Equity Comparison Engine

MXCT vs RCEL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RCEL Overall Edge

RCEL Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avita Medical, Inc. Common Stock (RCEL) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, MXCT trades at N/M Forward P/E with -85.5% operating margin (+48.7% YoY revenue) versus RCEL at 10.3x Forward P/E and -33.9% operating margin (+53.1% YoY). In options structure, MXCT sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against RCEL sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner RCEL
MXCT N/M vs RCEL 10.3x Fwd P/E
Growth & Margin Winner RCEL
Op Margin -85.5% vs -33.9% ยท YoY +48.7% vs +53.1%
Momentum & Technical Winner RCEL
1Y -19.4% vs +295.4% ยท 52W Pos 63% vs 82%
Options & Structure Winner RCEL
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (6th %ile IV)
MXCT NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
1M Return -4.2%
1Y Return -19.41%
Forward P/E N/M
Unified AI Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
RCEL NASDAQ
Avita Medical, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$15.62
-2.31% 1D
Market Cap $506.7M
1M Return +1.3%
1Y Return +295.44%
Forward P/E 10.3x
Unified AI Score
45.6 / 100 HOLD
Tech 32.0 Fund 44.0 Flow 69.0 Mom 31.1

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MXCT -19.41% RCEL +295.44% Spread: +314.85 pp (RCEL Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period MXCT Revenue RCEL Revenue MXCT Op. Margin RCEL Op. Margin Margin Edge
FY2018 N/A $0M N/A -1489.9% RCEL
FY2019 $10M $10M -93.7% -466.4% MXCT
FY2020 $20M $10M -71.6% -299.2% MXCT
FY2021 $20M $30M -84.3% -90.8% MXCT
FY2022 $30M $30M -95.2% -79.9% RCEL
FY2023 $20M $50M -247.7% -85.1% RCEL
FY2024 $20M $60M -230.5% -88.1% RCEL
FY2025 $20M $70M -247.6% -59.4% RCEL

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MXCT (1) vs RCEL (9)
Institutional Metric MXCT RCEL Criterion Row Winner
Market Capitalization Scale $132.2M $506.7M Larger Scale RCEL
Trailing P/E Ratio Valuation N/M 10.3x Lower Multiple RCEL
Forward P/E Ratio Valuation N/M 10.3x Lower Multiple RCEL
Revenue Growth (YoY) Growth +48.7% +53.1% Higher Growth RCEL
Operating Margin (TTM) Profitability -85.5% -33.9% Higher Margin RCEL
Net Profit Margin Profitability -81.4% -42.6% Higher Margin RCEL
Return on Equity (ROE) Capital Efficiency -16.9% -1746.3% Higher ROE MXCT
52-Week Range Position Momentum 63% ($1โ€“$2) 82% ($3โ€“$18) Stronger Trend RCEL
Beta / 30D Volatility Risk Regime 1.19ฮฒ ยท 96% Vol 1.54ฮฒ ยท 65% Vol Lower Realized Risk RCEL
Unified Institutional Score Composite Signal 41.7 / 100 (SELL) 45.6 / 100 (HOLD) Higher Composite RCEL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MXCT vs RCEL Buy Guide
MXCT UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MXCT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RCEL CONSOLIDATION
17d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live RCEL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MXCT nor RCEL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.